Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pankajkumar Vyas

Internal Medicine Benson, NC Medical Doctor

NPI 1376599647 CMS profile 334911

1 Medical Dr, Benson, NC 27504

Open in the dashboard

General payments

$13,794

632 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pankajkumar Vyas of Benson, NC is reported in the CMS Open Payments database as having received $13,794 across 632 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,195 59
2024 General $1,215 60
2023 General $1,288 78
2022 General $5,156 101
2021 General $2,287 127
2020 General $1,426 111
2019 General $1,228 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pankajkumar Vyas
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Pankajkumar Vyas were reported at $1,195. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Pankajkumar Vyas Internal Medicine median Middle half National median
2019 $1,228 $159 $48–$570 $163
2020 $1,426 $119 $33–$402 $114
2021 $2,287 $135 $37–$521 $132
2022 $5,156 $141 $42–$496 $149
2023 $1,288 $149 $45–$519 $160
2024 $1,215 $154 $47–$537 $164
2025 $1,195 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,466 61 payments
  2. Preventric Diagnostics, Inc. $1,183 2 payments
  3. Novo Nordisk Inc $797 55 payments
  4. Amgen Inc. $721 52 payments
  5. Pfizer Inc. $560 43 payments
  6. Janssen Pharmaceuticals, Inc $476 35 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $461 19 payments
  8. Esperion Therapeutics, Inc. $456 15 payments
  9. AstraZeneca Pharmaceuticals LP $450 32 payments
  10. Corcept Therapeutics $391 12 payments
  11. Other $4,833 306 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,257 629 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,500 1 payment
  3. Education $37 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $2,859 23 payments
  2. BPRO BT AMBULATORY BLOOD PRESSURE MONITORING SYSTEM $1,183 2 payments
  3. AIMOVIG $479 29 payments
  4. Kerendia $461 19 payments
  5. NEXLETOL $456 15 payments
  6. RYBELSUS $438 26 payments
  7. Korlym $391 12 payments
  8. Ozempic $371 31 payments
  9. VRAYLAR $367 21 payments
  10. Repatha $292 31 payments
  11. Other $9,494 631 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 298 drugs

Part D claims

46,021

Median for Internal Medicine: 777

Drug cost

$4,265,980

Median for Internal Medicine: $73,373

Branded share of claims

28.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 615 $663,918
Ozempic Semaglutide Brand 530 $542,744
Eliquis Apixaban Brand 681 $456,585
Trulicity Dulaglutide Brand 273 $269,079
Jardiance Empagliflozin Brand 238 $150,373
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 198 $144,332
Tresiba Flextouch U-200 Insulin Degludec Brand 109 $132,132
Tresiba Flextouch U-100 Insulin Degludec Brand 164 $96,311
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 277 $79,849
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 117 $76,118

The 10 drugs with the highest cost, of 298 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 231 billing codes

Paid by Medicare

$1,143,223

Of which drugs: $234,802

Medicare patients

682

Average age 75

Services billed

48,415

383 women, 299 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 48%
Arthritis 48%
Osteoporosis 44%
Chronic kidney disease 43%
Depression 34%
Ischemic heart disease 33%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 201 202 $59,000
Vaccine for Hepatitis B adult dosage (2 dose schedule) injection into muscle 90739 Office 156 263 $42,323
Injection, denosumab, 1 mg J0897 Office 20 1,800 $36,914
Injection, iron dextran, 50 mg J1750 Office 39 1,140 $15,758
Sarscv2 vac 30mcg trs-suc im 91320 Office 20 20 $2,958
Injection, zoledronic acid, 1 mg J3489 Office 63 320 $1,569
Injection, regadenoson, 0.1 mg J2785 Office 33 132 $787
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 93 2,850 $646
Injection, methylprednisolone acetate, 1 mg J1010 Office 42 5,200 $539
Injection, methylprednisolone acetate, 80 mg J1040 Office 24 35 $208

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $162
$162 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $118
$118 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $107
$107 64 —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $66
$66 — —
UBRELVY
  • AbbVie, Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

632 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record